Imagine cutting and pasting genes in DNA, just like editing a document. CRISPR-Cas9 gene editing technology does just that. Dubbed “the biggest biotech discovery of the century” supporters of CRISPR call out benefits such as potential cures for diseases like cancer, malaria, and cystic fibrosis; increased crop yields; and correcting genetic defects.

With the market for gene editing expected to reach $3.5 billion by 2019, pharmaceutical companies are jumping in. Can CRISPR eradicate viruses like AIDS and Zika? Can science control genetics?Rewriting DNA: Big Returns from Gene EditingSRI International Conference CenterTuesday, April 19, 2016

$10 Discount VLABOGE For registration see: http://bit.ly/VLAB2016-04-19

• 6:00 pm: Registration, Networking Reception & Demos. (Light food until 6:30pm)
• 7:00 pm to 8:30pm: Panel Discussion (Q&A)

Find out on April 19, 2016 at SRI during a lively panel discussion with leading experts.Moderator:

• Ted Driscoll, Parther & Digital Healthcare Lead, Claremont Creek Ventures

Panelists:

• Riley Doyle, CEO & Technical Lead, Desktop Genetics
• Edward Lanphier, President & CEO, Sangamo BioSciences
• Jenny Rooke, PhD & Managing Director, 5 Prime Ventures